Brand Names of Cefadroxil in Kenya
Actidrox®, Krishna Chemists Ltd
Adora®,Incepta Pharmaceuticals Limited
Biodroxil®, Sandoz GmbH Kundl
Bidcef®, Plethico
C-Drox®, Centurion Remedies Pvt. Ltd
Curisafe®, Pharco
Cedril®, Stallion
Cefamed®, Cipla
Cefdure®, Biodeal
Cefradox®, Aegis
Cesadroxyl®, Dabur
Cexil®, Leben Laboratories Pvt Ltd
Drox®, Aurobindo Pharma Limited
Duracef®, Bristol-Myers Squibb
Duraxyl®, Lab & Allied Ltd
Dawadroxyl®, Dawa Limited
Emdrox®, Medopharm
Ibidroxil®, GSK
Mydrox®, National Pharmacy Limited
Ococef DT®, Ochoa
Ococef®, Ochoa
Odoxil®, Lupin
Rivadroxil®, Riva
Vedrox®, Indoco Remedies Limited
Cefadroxil is a first-generation cephalosporin antibacterial drug that is the para-hydroxy derivative of cephalexin
CEFADROXIL MODE OF ACTION
cefadroxil binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis
INDICATIONS
Treatment of following infections caused by cefadroxil-susceptible organisms when an oral therapy is indicated:
– Streptococcal pharyngitis and tonsillitis
– Bronchopneumonia, bacterial pneumonia
– Uncomplicated urinary tract infections: pyelonephritis, cystitis
– Skin and soft tissue infections: abscesses, furunculosis, impetigo, erysipelas, pyoderma, lymphadenitis
Consideration should be given to official local guidance regarding the appropriate use of antibacterial agents.
DOSAGE AND ADMINISTRATION
Indication | Adults and adolescents > 40 kg with normal renal function | Children (< 40 kg) with normal renal function |
| Streptococcal pharyngitis / tonsillitis
| Dosage may be decreased to 1000 mg once a day over at least 10 days | 30 mg/kg/day once a day over at least 10 days |
| Bronchopneumonia, bacterial pneumonia | 1000 mg twice a day | 30-50 mg/kg/day divided into two daily doses |
| Urinary tract infections | 1000 mg twice a day | 30-50 mg/kg/day divided into two daily doses |
| Skin & soft tissue infections | 1000 mg twice a day | 30-50 mg/kg/day divided into two daily doses |
CONTRAINDICATIONS
– Hypersensitivity to cefadroxil, to any of the cephalosporins or to any of the excipients .
– History of severe reactions to penicillins or to any other beta-lactam drugs.
DRUG INTERACTIONS
Contraindication of concomitant use
– Cefadroxil should not be combined with bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) since an antagonistic effect is possible.
– Treatment with cefadroxil in combination with aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics should be avoided since such combinations can potentiate nephrotoxic effects.
Concomitant use not recommended
– Frequent checks on coagulation parameters are necessary during concomitant longterm use of anticoagulants or thrombocyte aggregation inhibitors to avoid haemorrhagic complications.
Precautions
– Cefadroxil binds to cholestyramine which may lead to reduced bioavailability of cefadroxil.
– The concomitant administration of probenecid reduces the renal elimination of cefadroxil; therefore, plasma concentrations of cefadroxil may be increased when given in combination with probenecid.
ADVERSE EFFECTS
System Organ Class | Common ≥1/100 to <1/10 | Uncommon ≥1/1,000 to <1/100 | Rare ≥1/10,000 to <1/1,000 | Very rare <1/10,000 |
| Infections and infestations | Clinical pictures due to a growth of opportunistic organisms (fungi), such as vaginal mycoses, thrush . | |||
| Blood and lymphatic system disorders | Eosinophilia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis: rare cases during prolonged used, which subside upon discontinuation of therapy. | Haemolytic anemia of immunologic origin. | ||
| Immune system disorders | Serum sickness-like reactions. | Immediate allergic reaction (anaphylactic shock) | ||
| Nervous system disorders | Headache, sleeplessness, dizziness, nervousness. | |||
| Gastrointestinal disorders | Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, glossitis . | Pseudomenbranous colitis has been reported (may range in severity from mild to life threatening) . | ||
| Hepatobiliary disorders | Cholestase and idiosyncratic hepatic failure have been reported. Minor elevation of serum transaminases (ASAT, ALAT) and alcaline phosphatases. | |||
| Skin and subcutaneous tissue disorders | Pruritus, rash, allergic exanthema, urticaria. | Angioneurotic edema. | Stevens Johnson syndrom and erythema multiforma have been reported. | |
| Musculoskeletal and connective tissue disorders | Arthralgia. | |||
| Renal and urinary disorders | Interstitial nephritis. | |||
| General disorders and administration site conditions | Drug fever. | Fatigue. | ||
| Investigations | Direct and indirect positive Coombs tests |
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:
Cefadroxil in Kenya
Cefadroxil in Kenya
Cefadroxil in Kenya
Cefadroxil in Kenya
Cefadroxil in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: B
Routes of Administration: Oral
Bioavailability: Not Available
Protein Binding: plasma protein
Metabolosim: unknown
Onset of Action: Not Available
Elimination Half life: 1.5 hours
Excretion: Not Available
Legal Status | Dosage forms & Strengths
Prescription Category:
Prescription only Medicine (POM) , â„ž-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Drug Indentifiers:
| CAS Number | |
|---|---|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | |
Drug Images
References/ Citation:
- PPB Drugs Retention Register
- Buck, R. E., and K. E. Price. “Cefadroxil, a new broad-spectrum cephalosporin.” Antimicrobial agents and chemotherapy 11.2 (1977): 324-330.
- Tanrisever, B., and P. J. Santella. “Cefadroxil.” Drugs 32.3 (1986): 1-16.
- La Rosa, F., et al. “Pharmacokinetics of cefadroxil after oral administration in humans.” Antimicrobial agents and chemotherapy 21.2 (1982): 320-322.